| Mike Szostak’s women’s basketball notes: PC’s Marandola ...
Chelsea Marandola decided in mid-December to forgo the current basketball season so she would have two full, healthy seasons remaining to play for Providence College. She is comfortable with her decision. "I'm feeling better, and the more you feel better, the happier you are," the high-scoring guard from Johnston said yesterday from Alumni Hall. She did, indeed, sound happy. Marandola is recovering ever so slowly from a herniated disk in her lower back. She suffered the injury during a workout last May and has been in physical therapy since July. She has seen a specialist in Boston and has had three cortisone injections. The last one worked the best, she said, because the doctor put the needle "right on the spot, but it hurt really badly." She may need another shot.
Multimillion-dollar bond for Curlin co-owners
.icoVid{background:url(http://msnbcmedia1.msn.com/i/msnbc/Components/Art/SITEWIDE/Icons/iVideo.gif) no-repeat center;padding-left:14px;text-decoration:none;position:static;} .icoVid:hover,.icoVid:visited:hover{text-decoration:none} .icoSli{background:url(http://msnbcmedia2.msn.com/i/msnbc/Components/Art/SITEWIDE/Icons/iSlides.gif) no-repeat center;padding-left:14px;text-decoration:none;position:static;} .icoSli:hover,.icoSli:visited:hover{text-decoration:none} .icoDis{background:url(http://msnbcmedia3.msn.com/i/msnbc/Components/Art/SITEWIDE/Icons/iDiscuss.gif) no-repeat center;padding-left:14px;text-decoration:none;position:static;} .icoDis:hover,.icoDis:visited:hover{text-decoration:none} .icoNew{background:url(http://msnbcmedia4.msn.com/i/msnbc/Components/Art/SITEWIDE/Icons/flag_new.gif) no-repeat center;padding-left:23px;text-decoration:none;position:static;} .icoNew:hover,.icoNew:visited:hover{text-decoration:none} .icoUpd{background:url(http://msnbcmedia3.msn.com/i/msnbc/Components/Art/SITEWIDE/Icons/flag_updated.gif) no-repeat center;padding-left:40px;text-decoration:none;position:static;} .icoUpd:hover,.icoUpd:visited:hover{text-decoration:none;} Skip navigation .
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR ...
PHILADELPHIA and WHITEHOUSE STATION, N.J., Nov. 26 /PRNewswire/ -- GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR(R) (lovastatin). Under the agreement, GSK will have exclusive rights to market non-prescription MEVACOR in the United States. Terms of the agreement are confidential but include milestone and royalty payments from GSK to Merck. MEVACOR was introduced in the United States in 1987 by Merck as the first in a class of cholesterol-reducing medicines known as "statins". The U.S. patent for MEVACOR expired in 2001. Commenting on the agreement, JP Garnier, chief executive officer, GlaxoSmithKline said, "This new partnership with Merck will enable GSK to address the important public health issue of high cholesterol and help patients better manage their health.
|
